Page 1083 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1048 ParT EighT Immunology of Neoplasia

80. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the 91. Tey SK. Adoptive T-cell therapy: adverse events and safety switches.
Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Clin Transl Immunology 2014;3(6):e17.
Review. JAMA Oncol 2016;2(10):1346–53. 92. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of
81. Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
in prostate cancer patients treated with ipilimumab: MD Anderson Sci Transl Med 2014;6(224):224ra25.
experience. Oncogene 2015;34(43):5411–17. 93. Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial
82. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab exploring the association between tumor microenvironment biomarkers
or monotherapy in untreated melanoma. N Engl J Med and clinical activity of ipilimumab in advanced melanoma. J Transl Med
2015;373(13):1270–1. 2011;9:204.
83. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of 94. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in
immune-related adverse events of special interest with ipilimumab: Cancer Immunotherapy. Mol Cancer Ther 2015;14(4):847–56.
detailed safety analysis from a phase 3 trial in patients with advanced 95. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway
melanoma. Cancer 2013;119(9):1675–82. blockade: combinations in the clinic. Front Oncol 2014;4:385.
84. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse 96. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4
events with immune checkpoint blockade: a comprehensive review. Eur combination blockade expands infiltrating T cells and reduces
J Cancer 2016;54:139–48. regulatory T and myeloid cells within B16 melanoma tumors.
85. Subudhi SK, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in Proc Natl Acad Sci USA 2010;107(9):4275–80.
the systemic circulation precedes development of ipilimumab-induced 97. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab
toxicities. Proc Natl Acad Sci USA 2016;113(42):11919–24. versus ipilimumab in untreated melanoma. N Engl J Med
86. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after 2015;372(21):2006–17.
antigen-specific immunotherapy of melanoma: direct evidence of t 98. Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1;
cell-mediated vitiligo. J Exp Med 2000;192(11):1637–44. BMS-936558, ONO-4538) in combination with sunitinib or pazopanib
87. Chandran SS, Paria BC, Srivastava AK, et al. Persistence of CTL clones in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin
targeting melanocyte differentiation antigens was insufficient to mediate Oncol 2014;32(Suppl.):5s, abstr 5010.
significant melanoma regression in humans. Clin Cancer Res 99. Sharma A, Bode B, Wenger RH, et al. gamma-Radiation promotes
2015;21(3):534–43. immunological recognition of cancer cells through increased expression
88. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell of cancer-testis antigens in vitro and in vivo. PLoS ONE
carcinoma with autologous T-lymphocytes genetically retargeted against 2011;6(11):e28217.
carbonic anhydrase IX: first clinical experience. J Clin Oncol 100. Sharma A, Bode B, Studer G, et al. Radiotherapy of human sarcoma
2006;24(13):e20–2. promotes an intratumoral immune effector signature. Clin Cancer Res
89. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and 2013;19(17):4843–53.
neurological toxicity following anti-MAGE-A3 TCR gene therapy. 101. Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint
J Immunother 2013;36(2):133–51. blockade immunotherapy: radiosensitisation and potential mechanisms
90. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis of synergy. Lancet Oncol 2015;16(13):e498–509.
and management of cytokine release syndrome. Blood
2014;124(2):188–95.